MRNA has now tripled in a week, yet the short book is bigger than it was before the INTerpath-001 catalyst — and the put/call ratio just set a new 52-week high.
The short-side behaviour this week is the defining tension. Bears did not capitulate. After brief covering in the immediate aftermath of the August 19 readout, shorts rebuilt aggressively — adding roughly 2.6 million shares in a single session on August 25 to bring the position back to 51.0 million shares, or 13.1% of the free float. That is above the level recorded the morning the Phase 3 data landed. The ORTEX short score has eased to 59.9 from 68.8 a week ago, consistent with some reduction in squeeze pressure — but the direction of the short book itself is unambiguously higher. These are not stale positions left open by inertia; new capital is arriving on the short side into a stock that closed Tuesday at $158.83, up 152% on the week.
The lending market does not currently validate a squeeze narrative. Availability has actually loosened, now running at 321% — meaning more than three shares remain unlent for every one already borrowed. That is up from around 217% on August 19 and close to the widest the pool has been all year. Cost to borrow is barely above zero at 0.53%, drifting modestly higher over the past month but nowhere near the distress level that would force involuntary covering. With 213 million shares still available and borrow costs negligible, a technical squeeze is not what the lending market is pricing. What it is pricing is a large, active, and apparently growing bet that the stock has overshot. Options traders agree on the defensive read: the put/call ratio hit 1.54 on Tuesday — a new 52-week high and 2.3 standard deviations above its 20-day average of 1.22. The last time the PCR was anywhere close to this level was a brief spike in mid-July.
The Street spent the week chasing the price rather than leading it, and the gap between analyst targets and the current quote is striking. Goldman Sachs raised its target from $67 to $120 and held Neutral. JP Morgan lifted from $40 to $77 while keeping Underweight. Barclays moved its target from $48 to $125 at Equal-Weight. Morgan Stanley went from $39 to $89 at Equal-Weight. The pattern is consistent: every major bank raised targets dramatically — in some cases tripling or quadrupling their prior figures — without changing the underlying rating. The consensus mean target now sits around $104, roughly 34% below Tuesday's close of $158.83. Wolfe Research upgraded to Peer Perform on August 25, and William Blair moved to Outperform on August 19, but neither came with a published target. The broad message from the Street is that the INTerpath-001 data materially changes the fundamental picture, yet most analysts remain reluctant to endorse a price that has already run well past their revised figures.
Institutional positioning and insider activity add further texture to the skepticism. CEO Stéphane Bancel sold more than 499,000 shares on August 5 — before the catalyst — at prices between $56 and $59, generating roughly $28.7 million in proceeds. President Stephen Hoge sold 53,336 shares at $67.60 on July 15, also pre-catalyst. These were not post-rally exits; they were scheduled sales into what was then a depressed price. Bancel still holds 22.2 million shares, roughly 5.6% of the company, so his economic alignment remains substantial. Among the top institutional holders, FMR added 6.1 million shares through June 30, and Capital Research added 3.6 million. Two Sigma trimmed nearly 1.9 million shares. The aggregate insider net over 90 days is modestly positive in share terms, though the dollar value of sells dominates given the timing. Close peer BNTX gained 23% on the week, and ARCT surged 88%, suggesting the mRNA theme broadly caught a bid — though Arcturus is a much smaller name and its move likely reflects speculative read-across rather than comparable fundamentals.
The next scheduled event is a November 5 earnings print. Between now and then, the contest is simple to frame: bears at 13% of the float are betting the stock has priced in more than the INTerpath-001 data can deliver, while the loosening borrow pool and negligible cost to borrow tell them the trade is cheap to maintain — the question is whether the stock gives them a reason to stay.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
